Sintilimab-IFN alpha fusion protein (Innovent Biologics)

N/A

Report date: 2025/06/06 10:36:37

Base Information

Drug NameSintilimab-IFN alpha fusion protein (Innovent Biologics)
Drug Alias NamePD1-IFN alpha fusion protein
ClassificationBiologics > Protein drugs > Recombinant protein > Fusion protein
Mechanisms of ActionProgrammed cell death protein 1 blockersInterferon alpha replacements
TargetsProgrammed cell death protein 1Interferon alpha
Therapy Area/IndicationsSolid tumours
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaPreclinical
Originator CompaniesInnovent Biologics Inc
China Registration ClassN/A

Develop Information

Active CompaniesInnovent Biologics Inc
Inactive CompaniesN/A
Active IndicationsSolid tumours
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A